Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.

Hussain, M; Mateo, J; Fizazi, K; Saad, F; Shore, N; Sandhu, S; Chi, KN; Sartor, O; Agarwal, N; Olmos, D; Thiery-Vuillemin, A; Twardowski, P; Roubaud, G; Özgüroğlu, MUSTAFA; Kang, J; Burgents, J; Gresty, C; Corcoran, C; Adelman, CA; de, Bono; PROfound, Trial

doi:10.1056/nejmoa2022485

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.

Hussain M., Mateo J., Fizazi K., Saad F., Shore N., Sandhu S., ...Daha Fazla

The New England journal of medicine, cilt.383, ss.2345-2357, 2020 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 383
Basım Tarihi: 2020
Doi Numarası: 10.1056/nejmoa2022485
Dergi Adı: The New England journal of medicine
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, Abstracts in Social Gerontology, AgeLine, BIOSIS, CAB Abstracts, Chemical Abstracts Core, CINAHL, Educational research abstracts (ERA), EMBASE, Food Science & Technology Abstracts, Gender Studies Database, International Pharmaceutical Abstracts, MEDLINE, MLA - Modern Language Association Database, Public Affairs Index, Veterinary Science Database
Sayfa Sayıları: ss.2345-2357
İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

BackgroundWe previously reported that olaparib led to significantly longer imaging-based progression-free survival than the physician's choice of enzalutamide or abiraterone among men with metastatic castration-resistant prostate cancer who had qualifying alterations in homologous recombination repair genes and whose disease had progressed during previous treatment with a next-generation hormonal agent. The results of the final analysis of overall survival have not yet been reported.